Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
Journal Article (Journal Article)
The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.
Full Text
Duke Authors
Cited Authors
- Doolittle, ND; Abrey, LE; Ferrari, N; Hall, WA; Laws, ER; McLendon, RE; Muldoon, LL; Peereboom, D; Peterson, DR; Reynolds, CP; Senter, P; Neuwelt, EA
Published Date
- June 2002
Published In
Volume / Issue
- 8 / 6
Start / End Page
- 1702 - 1709
PubMed ID
- 12060607
International Standard Serial Number (ISSN)
- 1078-0432
Language
- eng
Conference Location
- United States